Eli Lilly & Company Foundation
VC Fund
Indianapolis, United States
Eli Lilly & Company Foundation is an organization that supports programs designed to improve patient outcomes and enhance the quality of life. The organization makes strategic and philanthropic investments consistent with Lilly’s purpose. It also supports improving educational opportunities for children living in underserved communities inIndianapolis. Eli Lilly & Company Foundation focuses on early childhood education, supporting quality schools and STEM (science, technology, engineering, and math) education. The foundation was established in 1968 and is based in Indianapolis, Indiana.
- Total investments:
- 27
- Last investment:
- Lead investor:
- 19%
Last updated:
For AI agents: llms.txt
Industries Eli Lilly & Company Foundation invests in
Stages Eli Lilly & Company Foundation invests in
Countries Eli Lilly & Company Foundation invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Anish Konkar
|
|||
|
Denis Cusack
|
|||
|
Ed Morris
|
|||
|
Eli Lilly
|
|||
Jacob Van Naarden
|
Investment Focus
Industry
- Biotechnology 19 (70%)
- Therapeutics 12 (44%)
- Health Care 10 (37%)
- Medical 4 (15%)
- Biopharma 4 (15%)
Stage
- Series A 10 (37%)
- Series B 5 (19%)
- Grant 3 (11%)
- Series C 3 (11%)
- Seed 2 (7%)
Country
- United States 21 (78%)
- United Kingdom 1 (4%)
- The Netherlands 1 (4%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Anish Konkar
Scientist
|
Scientist | Total investments: 0 | Find email | |
|
Denis Cusack
Project recruiter
|
Project recruiter | Total investments: 0 | Find email | |
|
Ed Morris
Project Manager
|
Project Manager | Total investments: 0 | Find email | |
|
Eli Lilly
Founder
|
Founder | Total investments: 0 | Find email | |
|
Jacob Van Naarden
President
|
President | Total investments: 2 | Find email | |
| See all 14 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Partners In Health
|
Partners in Health is a charitable organisation that provides comprehensive health care to individuals in the developing world. | $3.6M / Grant / Jun 09, 2026 | |
TRex Bio
|
TRexBio is a discovery stage biotechnology company leveraging cutting-edge computational biology tools, a focus on human tissue, and expertise in immunobiology to develop revolutionary therapeutics for cancer and inflammatory diseases. Our powerful ‘deep biology’ discovery engine maps human tissue Treg behavior to disease processes, allowing us toidentify and characterize novel targets for therapeutic intervention. Leveraging this platform, we are building a broad portfolio of novel therapies that modulate the immune system to restore human tissue immune homeostasis. | $50M / Jan 27, 2026 | |
Incyclix Bio
|
Incyclix Bio develops small molecule inhibitors of CDKs for the treatment of advanced and resistant cancers. Founded by Patrick Roberts, Jay Strum, John Bisi, and Fred Eshelman in 2020 and is headquartered in Durham, North Carolina. | $11.2M / Series B / Aug 22, 2025 | |
Strand Therapeutics
|
Strand Therapeutics is a developer of a biotechnology platform intended to create gene therapies powered by synthetic biology.The company's offerings include immunotherapies to help cells produce target cancer-killing proteins during immunotherapy, enabling patients to improve their body's immune system to fight cancer. | $153M / Series B / Aug 03, 2025 | |
|
TRex Bio
|
TRexBio is a discovery stage biotechnology company leveraging cutting-edge computational biology tools, a focus on human tissue, and expertise in immunobiology to develop revolutionary therapeutics for cancer and inflammatory diseases. Our powerful ‘deep biology’ discovery engine maps human tissue Treg behavior to disease processes, allowing us toidentify and characterize novel targets for therapeutic intervention. Leveraging this platform, we are building a broad portfolio of novel therapies that modulate the immune system to restore human tissue immune homeostasis. | $84M / Series B / Nov 13, 2024 | |
Arda Therapeutics
|
Arda Therapeutics is a biotechnology company taking aim at chronic diseases and aging by eliminating the pathogenic cells that drive these conditions. Their approach starts by using single-cell data to identify pathogenic cells and specific markers to target them. They then design therapies to eliminate these - and only these - cells.Arda wasfounded in 2021 in the San Francisco Bay Area, CA. | $43M / Series A / Oct 01, 2024 | |
Elektrofi
|
Elektrofi is a preclinical-stage company dedicated to redefining the standard of drug delivery by transforming the patient experience. Elektrofi’s formulation system can effectively process a wide range of therapeutic molecules. Their technology has the capacity to process large, increasingly complex and delicate proteins including monoclonalantibodies, bispecifics and fusion proteins.Founded in 2016, Elektrofi is based in Boston, Massachusetts, United States. | $112.3M / Series C / Aug 22, 2024 | |
Artax Biopharma
|
Artax Biopharma is a development-stage biopharmaceutical company that is dedicated to the development of new therapies for autoimmune and inflammatory diseases. Its technology provides the compounds with the potential to become first-in-class immunomodulators for the treatment of a wide range of autoimmune and inflammatory diseases.The companywas founded in 2013 and is headquartered in Cambridge, Massachusetts. | $8M / Convertible Note / Aug 06, 2024 | |
Ajax Therapeutics
|
Ajax Therapeutics develops targeted therapies for hematologic cancers, with a focus on treating myeloproliferative neoplasms through precision drug discovery approaches. The company applies computational chemistry and structural biology to design small-molecule therapies that selectively target disease-driving proteins while minimizing off-targeteffects. Its research centers on next-generation inhibitors of the JAK2 protein, a key driver of certain blood cancers, using a differentiated mechanism that binds the Type II conformation of the kinase. This approach aims to improve treatment effectiveness and address limitations of existing therapies that provide symptom relief but do not fully suppress disease progression. It integrates discovery, preclinical research, and clinical development within its operating model, enabling continuous refinement of drug candidates based on biological insights and trial data. It collaborates with research institutions and leverages scientific expertise in oncology and molecular medicine to support development efforts. | $95M / Series C / May 13, 2024 | |
Capstan Therapeutics
|
Capstan Therapeutics is advancing precision in vivo cell engineering to develop therapeutics for a broad range of disease categories with unmet or underserved clinical need. | $175M / Series B / Mar 20, 2024 | |
| See all 27 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Eli Lilly & Company Foundation invest in?
Eli Lilly & Company Foundation invests primarily in Biotechnology, Therapeutics and Health Care startups, most often at Series A and Series B stage. Most of the 27 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Eli Lilly & Company Foundation?
Public channels for Eli Lilly & Company Foundation include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Eli Lilly & Company Foundation?
The team at Eli Lilly & Company Foundation includes Anish Konkar (Scientist), Denis Cusack (Project recruiter) and Ed Morris (Project Manager), among 14 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
